{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.5","upperLimit":"55.7","value":"44.4"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.8","upperLimit":"59.5","value":"48.2"}]}],"title":"9 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.6","upperLimit":"64.5","value":"52.9"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.0","upperLimit":"78.5","value":"64.8"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Defined as the proportion of subjects who died due to causes other than malignancy relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants began oral administration of ruxolitinib at 5 mg BID; if stable after the first 3 days of treatment, the dose may be increased to 10 mg BID. Participants did receive prednisone 2.5 mg/kg per day orally (PO) or methylprednisolone 2.0 mg/kg per day IV.","id":"OG000","title":"Ruxolitinib in Combination With Corticosteroids"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Participants including all responders as of the data cutoff (02 JUL 2018).","reportingStatus":"POSTED","timeFrame":"From baseline to Months 6, 9, 12, and 24","title":"Nonrelapse Mortality (NRM)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}